David Melamed, PhD,  —

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

Articles by

UK Approves Phase 1 Trial of Potential Gene Editing Therapy, NTLA-2001

A Phase 1 trial of NTLA-2001, a potential gene editing therapy for  familial amyloid polyneuropathy (FAP), was approved to open by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). Intellia Therapeutics is planning to launch the open-label and two-part trial in people with hereditary transthyretin amyloidosis (ATTR) with polyneuropathy before…